Suggested remit: To appraise the clinical and cost effectiveness of durvalumab within its marketing authorisation for induction and maintenance treatment of untreated advanced or recurrent endometrial cancer.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6317

Provisional Schedule

Final draft guidance 12 June 2025 - 10 July 2025

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ

Stakeholders

Companies sponsors AstraZeneca (durvalumab, olaparib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Peaches Womb Cancer Trust
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Accord (carboplatin, paclitaxel, cisplatin, doxorubicin) (confidentiality agreement not signed, not participating)
  Alliance Healthcare (cisplatin, cyclophosphamide, paclitaxel) (confidentiality agreement not signed, not participating)
  Bausch & Lomb (megestrol acetate) (confidentiality agreement not signed, not participating)
  Baxter Healthcare (cyclophosphamide) (confidentiality agreement not signed, not participating)
  Bristol Myers Squibb Pharmaceuticals (paclitaxel) (confidentiality agreement not signed, not participating)
  Consilient Health (carboplatin) (confidentiality agreement not signed, not participating)
  Fresenius Kabi (carboplatin, paclitaxel) (confidentiality agreement not signed, not participating)
  Hospira UK (carboplatin, paclitaxel) (confidentiality agreement not signed, not participating)
  Medac GmbH (doxorubicin) (confidentiality agreement not signed, not participating)
  Pfizer (carboplatin, paclitaxel, cisplatin,
  doxorubicin, medroxyprogesterone
  acetate) (confidentiality agreement not signed, not participating)
  Sandoz (cisplatin, cyclophosphamide) (confidentiality agreement not signed, not participating)
  Seacross Pharmaceuticals (paclitaxel, doxorubicin) (confidentiality agreement not signed, not participating)
  Teva UK (carboplatin, cisplatin, paclitaxel) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  NHS Wales Joint Commissioning Committee
Relevant research groups Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
26 June 2025 NICE has been made aware of some inconsistencies regarding the appeal process for this appraisal. As a result, the publication of final guidance will be delayed and consultees will have the opportunity to submit appeals until 5pm Thursday 10 July.
06 May 2025 Committee meeting: 2
06 May 2025 Declaration of interests
26 March 2025 - 16 April 2025 Draft guidance
04 March 2025 Committee meeting: 1
30 July 2024 Invitation to participate
25 March 2024 - 10 April 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6317
24 January 2024 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late July 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
08 December 2023 - 15 January 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6317
08 December 2023 In progress. Scoping commencing
02 May 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual